Clinical development of passive tau-based immunotherapeutics for treating primary and secondary tauopathies

Francesco Panza, Vittorio Dibello, Rodolfo Sardone, Fabio Castellana, Roberta Zupo, Luisa Lampignano, Ilaria Bortone, Roberta Stallone, Nicoletta Cirillo, Christian Damiani, Mario Altamura, Antonello Bellomo, Antonio Daniele, Vincenzo Solfrizzi, Madia Lozupone

Risultato della ricerca: Contributo in rivistaArticolo in rivista

Abstract

IntroductionTauopathies are clinicopathological entities with increased and pathological deposition in glia and/or neurons of hyperphosphorylated aggregates of the microtubule-binding protein tau. In secondary tauopathies, i.e. Alzheimer's disease (AD), tau deposition can be observed, but tau coexists with another protein (amyloid-& beta;). In the last 20 years, little progress has been made in developing disease-modifying drugs for primary and secondary tauopathies and available symptomatic drugs have limited efficacy.Areas coveredThe present review summarized recent advances about the development and challenges in treatments for primary and secondary tauopathies, with a focus on passive tau-based immunotherapy.Expert opinionSeveral tau-targeted passive immunotherapeutics are in development for treating tauopathies. At present, 14 anti-tau antibodies have entered clinical trials, and 9 of them are still in clinical testing for progressive supranuclear palsy syndrome and AD (semorinemab, bepranemab, E2814, JNJ-63733657, Lu AF87908, APNmAb005, MK-2214, PNT00, and PRX005). However, none of these nine agents have reached Phase III. The most advanced anti-tau monoclonal antibody for treating AD is semorinemab, while bepranemab is the only anti-tau monoclonal antibody still in clinical testing for treating progressive supranuclear palsy syndrome. Further evidence on passive immunotherapeutics for treating primary and secondary tauopathies will come from ongoing Phase I/II trials.
Lingua originaleEnglish
pagine (da-a)625-634
Numero di pagine20
RivistaExpert Opinion on Investigational Drugs
Volume32
DOI
Stato di pubblicazionePubblicato - 2023

Keywords

  • Alzheimer’s disease
  • FTLD-Tau
  • PSPS
  • tauopathies
  • mild cognitive impairment
  • monoclonal antibodies
  • tau
  • dementia

Fingerprint

Entra nei temi di ricerca di 'Clinical development of passive tau-based immunotherapeutics for treating primary and secondary tauopathies'. Insieme formano una fingerprint unica.

Cita questo